Login to Your Account



ChemoCentryx Partners With GSK's CEEDD In $1.5B Deal

By Karen Pihl-Carey


Friday, August 25, 2006
In a worldwide multi-target alliance focused on treatments for inflammatory disorders, ChemoCentryx Inc. signed a deal potentially worth $1.5 billion with GlaxoSmithKline plc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription